BioMarin Pharmaceutical Inc. (BMRN) A Stock that Could 10x by 2030 on Pipeline Development

The cautious outlook comes connected the heels of BioMarin Pharmaceutical delivering affirmative Phase 3 Pivotal survey results for VOXZOGO. The survey met the superior endpoint successful children with hypochondroplasia and exceeded expectations, with a highly statistically important betterment successful annualized maturation velocity (AGV).

Safety findings were besides successful enactment with the established illustration successful achondroplasia. Hypochondroplasia is simply a uncommon familial upset characterized by impaired bony growth, resulting successful disproportionate abbreviated stature and skeletal abnormalities.

For the archetypal time, a Phase 3 survey of hypochondroplasia has demonstrated awesome gains successful growth, including improvements successful limb span. Consequently, BioMarin Pharmaceutical intends to taxable a supplemental New Drug Application to the US Food and Drug Administration successful the 3rd quarter. It besides plans to marque submissions to the European Medicines Agency.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is simply a planetary biotechnology institution that develops and commercializes innovative therapies for uncommon and ultra-rare familial diseases. It is simply a pioneer successful enzyme replacement therapies (ERT) and cistron therapy.

While we admit the imaginable of BMRN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Oil Stocks to Buy Now Amid the US-Iran Conflict and 14 Best 52-Week High Stocks to Invest In According to Short Sellers.

Disclosure: None. Follow Insider Monkey connected Google News.